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Background: Essential thrombocythemia (ET) is classiﬁed as a chronic myeloproliferative neoplasm. JAK2
V617F mutation is found in about 50e60% patients with ET. We aim to determine the prevalence of JAK2
V617F mutation and its association with phenotype in adult Taiwanese patients with ET.
Methods: In this combined retrospective and prospective study, adult ET patients, at least 18 years of age,
were enrolled between November 2007 and September 2011. Genomic DNAwas extracted from unsorted
bone marrow and/or peripheral blood samples for the detection of JAK2 V617F mutation by allele-speciﬁc
polymerase chain reaction. The clinical and laboratory characteristics of all patients at the time of
diagnosis or referral were determined retrospectively by chart review.
Results: A total of 82 patients were enrolled, and JAK2 V617F mutationwas detected in 55 patients (67.1%).
JAK2 V617F mutation was signiﬁcantly more prevalent in old patients (36.4% vs. 14.8%, p¼ 0.044), and
associated with higher hemoglobin level (median 13.7 vs. 12.8 g/dL p¼ 0.012) and higher white blood cell
count at diagnosis (12.1 103 vs. 8.8 103/mL p¼ 0.015). ET patients with the mutation also tend to have
lower platelet count (median 902 103 vs. 1078 103/mL p¼ 0.051). In a binary logistic regression model,
only higher hemoglobin concentration was signiﬁcantly associated with JAK2 V617F mutational status
(odds ratio 1.2 95% conﬁdence interval 1.0e1.5; p¼ 0.047).
Conclusion: JAK2 V617F mutation in Taiwanese adult patients with ET has a high prevalence of 67.1% and
is associated with old age, higher hemoglobin level, and higher leukocyte count.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Essential thrombocythemia (ET) is classiﬁed as one of the BCR-
ABL1-negative classic chronic myeloproliferative neoplasms
(MPNs), which also include polycythemia vera and primary
myeloﬁbrosis1. ET is a clonal stem cell disorder and is characterized
by excessive platelet production, usually without obviousf Hematology and Oncology,
Hospital, No. 92, Section 2,
).
iwan Society of Geriatric Emergenpanmyelosis feature, in the bone marrow2e4. Clinically, ET patients
have a near-normal life expectancy5,6. Although a large number of
ET patients may be asymptomatic at presentation, they may report
vasomotor symptoms such as headache, lightheadedness, or
erythromelalgia. Furthermore, some patients may experience
thrombotic or hemorrhagic complications, which are related to
qualitative and quantitative platelet alterations7,8. In some rare
cases, disease transformation to polycythemia vera, secondary
myeloﬁbrosis, or acute leukemia may also be seen. Therefore,
patients with ET require long-term clinical follow-up.
The diagnosis of ET is more challenging than other MPNs
because no speciﬁc clinical, pathological, or molecular features are
unique to ET, which is currently diagnosed by exclusion2. In thecy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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requires the fulﬁllment of all the following four major criteria: (1)
the clinical ﬁnding of a sustained and otherwise unexplained
thrombocytosis (450103/mL); (2) the exclusion of other myeloid
disorders including polycythemia vera, primary myeloﬁbrosis,
chronic myeloid leukemia, and myelodysplastic syndrome; (3) the
proliferation of megakaryocytes without obvious atypia, and there
is no granulocytic proliferation in the bonemarrow; and (4) a clonal
marker such as JAK2 V617F or TET2 mutation9 or the exclusion of
secondary thrombocytosis. Since its ﬁrst discovery in 2005, the
JAK2 V617F mutation has important diagnostic and therapeutic
implications in classic MPNs including ET10e13. JAK2 V617F muta-
tion results from a single-point mutation (G / T transversion)
encoding a valine-to-phenylalanine substitution at position 617 in
exon 14 of the JAK2 gene. The autoinhibitory action of JH2 domain
in JAK2 gene is triggered in V617F mutation, which results in
a constitutively activated JAK2 tyrosine kinase. The prevalence of
JAK2 V617F mutation is reported in approximately 50e60% of
patients with ET and primary myeloﬁbrosis, and the incidence rate
could rise up to more than 90% in polycythemia vera7,14,15. In the
2008 World Health Organization classiﬁcation, the JAK2 V617F
mutation has been incorporated as one of the clonal marker,
although not speciﬁc, for ET2. In addition, several JAK2 inhibitors
have been developed to target the JAK-STAT signaling pathway. The
success of JAK inhibitor in the treatment of myeloﬁbrosis has
further proved that JAK-STAT signaling is important in the patho-
genesis of MPNs16,17.
The presence of JAK2 V617F mutation in ET patients has been
shown to be associated with some clinical and laboratory features,
including a higher incidence of thrombosis, higher total white
blood cell (WBC) counts and hemoglobin concentration, and lower
platelet counts16e21. However, not all the above-mentioned
features were found in each individual study. In the current
study, we aim to determine the prevalence of JAK2 V617F mutation
by allele-speciﬁc polymerase chain reaction (AS PCR) in a cohort of
Taiwanese adult patients with ET. The association between JAK2
V617F mutation and clinical and laboratory characteristics at
diagnosis or referral was also studied.2. Patients and methods
2.1. Patients
This study was approved by the Institutional Review Board of
the Mackay Memorial Hospital. Clinical samples were obtained
between November 2007 and September 2011, and all patients
provided written informed consent. The diagnosis of ET was based
on the 2008 World Health Organization classiﬁcation. Adult
patients with ET who were at least 18 years of age and have
received clinical follow-up at our hospital were enrolled retro-
spectively or prospectively. The clinical and laboratory character-
istics of all patients at the time of diagnosis or referral were
determined retrospectively by chart review.2.2. Genomic DNA extraction
Unsorted bone marrow and/or peripheral blood WBCs were
collected by using red blood cell lysis buffer. Peripheral blood
mononuclear cells and/or granulocytes were isolated by usingFi-
coll-Paque PLUS (GE Healthcare, Salt Lake, UT, USA) density
gradient separation according to the standard procedures. Genomic
DNA was extracted using EasyPure Genomic DNA Spin Kit(Bioman,
Taipei, Taiwan) for blood cells according to the manufacturer’s
instructions.2.3. JAK2 V617F allele-speciﬁc polymerase chain reaction
The JAK2 V617F AS primers that were used are as follows:
speciﬁc forward primer (for the V617F allele mutant): 50-
AGCATTTGGTTTTAAATTATGGAGTATATT-30, with an introduced
mismatch at the third nucleotide from 30-end (203-bp product);
JAK2 exon 14 control forward primer: 50-ATCTA-
TAGTCATGCTGAAAGTAGGAGAAAG-30 (364-bp product); and the
reverse primer: 50-CTGAATAGTCCTACAGTGTTTTCAGTTTCA-3011.
The 12.5 mL JAK2 AS PCR reaction volume incorporated 50 ng of
template DNA, 6.25 mL of 2GoTaq Green Master Mix PCR buffer
(Promega, Madison, CA, USA), and 1 mL from each of the 5 mM
forward and reverse primers. The PCR ampliﬁcation conditions
were as follows: initial denaturation at 95C for 5 minutes; 36
cycles of 95C for 30 seconds, 55C for 30 seconds, and 72C for 45
seconds; and ﬁnal extension at 72C for 10 minutes. The size and
speciﬁcity of the products were conﬁrmed by gel electrophoresis.
The sensitivity of JAK2 V617F AS PCR was determined to be 5% by
serial dilution of JAK2 V617F DNA (HEL, human erythroleukemia
cell) in JAK2V617 wild-type control DNA (K562, human eryth-
romyeloblastoid leukemia cell).
2.4. Statistical analyses
The association between JAK2 V617F mutational status and
clinical characteristics was calculated by the chi-square test or
Fisher’s exact test. The comparison between categorical and
continuous variables was performed by the ManneWhitney U test.
Correlation between two continuous variables was determined
with the nonparametric Spearman rankeorder correlation coefﬁ-
cient. The binary logistic regression was used for multivariate
analysis. Statistical signiﬁcance was deﬁned as a two-sided p value
<0.05. Statistical analyses of the data were carried out by using the
SPSS Statistics software (IBM, Armonk, NY, USA).
3. Results
The present study cohort enrolled 82 Taiwanese adult patients
with ET, including 36 males and 46 females. The median age at
diagnosis was 53.5 years (range 22e89 years). The median time
from the diagnosis of ET to patient enrollment into the study was
2.9 years (range 0e22.0 years). The clinical and laboratory charac-
teristics of these patients at diagnosis or referral are presented in
Table 1. Overall, the JAK2 V617F mutation was identiﬁed in 55
patients (67.1%). There were no signiﬁcant differences in age at
diagnosis, gender, disease duration, asymptomatic at presentation,
the presence of vasomotor symptoms, or history of thrombotic and
hemorrhagic complications between those with and those without
the mutation. There were also no differences in gender, disease
duration, asymptomatic at presentation, the presence of vasomotor
symptoms, or history of thrombotic and hemorrhagic complica-
tions including both major and minor events between old and
young patients. However, JAK2 V617F mutation was signiﬁcantly
more prevalent in old patients (36.4% vs. 14.8%, p¼ 0.044). In
addition, hemoglobin concentration and WBC count at diagnosis
were signiﬁcantly higher in ET patients with the mutation (median
13.7 vs. 12.8 g/dL, p¼ 0.012; 12.1103 vs. 8.8 103/mL, p¼ 0.015,
respectively). There was a trend that ET patients with the mutation
had lower platelet count (median 902103 vs. 1078 103/mL,
p¼ 0.051).
The present study also analyzed the association between old age
and the three laboratory parameters. Old age did not correlate with
hemoglobin concentration, and WBC and platelet counts. Hemo-
globin concentration also did not correlate with WBC count
(p¼ 0.6), but it showed statistically signiﬁcant negative correlation
Table 1
Clinical and laboratory characteristics at diagnosis or referral of 82 adult Taiwanese patients with essential thrombocythemia.
Characteristic No. of patients
(n¼ 82) No. (%)
Age 65 y JAK2 V617F mutation
Yes (n¼ 24) No. (%) No (n¼ 58) No. (%) p Positive (n¼ 55) No. (%) Negative (n¼ 27) No. (%) p
Time from diagnosis to
enrolment, y (n¼ 75)
2.9 (0e22.0) 2.8 (0e8.0) 3.0 (0e22.0) 0.5a 3.0 (0e22.0) 2.6 (0e11.6) 0.9a
Median (MineMax)
Age at diagnosis, y 53.5 (22e89) d d d 54 (22e89) 52 (25e79) 0.3a
Median (MineMax)
Follow-up, mo 44.8 (0.3e274.8) 41.4 (0.9e151.4) 46.0 (0.3e274.8) 0.3a 42.1 (0.3e274.8) 56.0 (2.1e158.3) 0.1a
Median (MineMax)
Age 65 y 24 (29.3) d d d 20 (36.4) 4 (14.8) 0.044
Male sex 36 (43.9) 13 (54.2) 23 (39.7) 0.2 25 (45.4) 11 (40.7) 0.7
Asymptomatic 34 (41.5) 10 (41.7) 24 (41.4) 1.0 20 (36.4) 14 (51.9) 0.2
Vasomotor symptoms 23 (28.0) 7 (29.2) 16 (27.6) 1.0b 18 (32.7) 5 (18.5) 0.2b
Dizziness 17 (20.7) 6 (25.0) 11 (19.0) 0.6b 13 (23.6) 4 (14.8) 0.4b
Headache 7 (8.5) 1 (4.2) 6 (10.3) 0.7b 5 (9.1) 2 (7.4) 1.0b
Acral paresthesia 3 (3.7) 2 (8.3) 1 (1.7) 0.2b 2 (3.6) 1 (3.7) 1.0b
History of thrombosis 13 (15.9) 5 (20.8) 8 (13.8) 0.5b 9 (16.4) 4 (14.8) 1.0b
Major arterial thrombosis 9 (11.0) 4 (16.7) 5 (8.6) 0.4b 6 (10.9) 3 (11.1) 1.0b
Major venous thrombosis 3 (3.7) 1 (4.2) 2 (3.4) 1.0b 2 (3.6) 1 (3.7) 1.0b
Minor thrombosis 2 (2.4) 0 2 (3.4) 1.0b 1 (1.8) 1 (3.7) 1.0b
History of hemorrhage 9 (11.0) 4 (16.7) 5 (8.6) 0.4b 6 (10.9) 3 (11.1) 1.0b
Major hemorrhage 7 (8.5) 4 (16.7) 3 (5.2) 0.2b 4 (7.3) 3 (11.1) 0.7b
Minor hemorrhage 2 (2.4) 0 2 (3.4) 1.0b 2 (3.6) 0 1.0b
Splenomegalyc 21 (25.6) 4 (16.7) 17 (29.3) 0.2 15 (27.3) 6 (22.2) 0.8b
Hemoglobin (g/dL) 13.3 (4.5e17.9) 13.1 (9.6e17.6) 13.4 (4.5e17.9) 1.0a 13.7 (4.5e17.9) 12.8 (8.5e15.2) 0.012a
Median (MineMax)
WBC (103/mL) 10.3 (4.8e29.9) 12.3 (6.0e29.9) 10.0 (4.8e29.3) 0.3a 12.1 (4.8e29.9) 8.8 (4.9e27.9) 0.015a
Median (MineMax)
Platelet (103/mL) 944 (335e2834) 952 (339e1496) 944 (335e2834) 0.8a 902 (335e1931) 1078 (532e2834) 0.051a
Median (MineMax)
Max¼maximal; Min¼minimal; WBC¼white blood cell; d¼ not evaluated.
a ManneWhitney U test; otherwise chi-square test was applied.
b Fisher’s exact test.
c Including physical and imaging evaluation.
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a binary logistic regression model, old age, hemoglobin concen-
tration, and WBC count were selected as covariates and JAK2 V617F
mutational status as a dependent variable. Only higher hemoglobin
concentration remained signiﬁcantly associated with JAK2 V617F
mutational status in this model (odds ratio 1.2, 95% conﬁdence
interval 1.0e1.5; p¼ 0.048).
The median follow-up time for all 82 patients was 44.8 months
from diagnosis (range 0.3e274.8 months). During this period, two
ET patients with JAK2 V617F mutation underwent disease trans-
formation to acute myeloid leukemia and expired at 147.08 and
103.9 months after diagnosis, respectively. All the remaining 80
patients were still alive without transformation. No signiﬁcant
difference was seen in the degree of disease transformation into
acute myeloid leukemia between the twomutational groups in this
cohort. Due to very few survival events, median survival was not
reached and could not be compared between different groups.
4. Discussion
In the present study, the prevalence of JAK2 V617F mutation in
Taiwanese adult patients with ET was determined as 67%. Recently,
the prevalence of JAK2 V617F mutation in Chinese or Taiwanese
patients with ET was also reported by several studies21e25, and the
incidence rate is ranged from 34% to 66%. When compared to other
studies, the incidence of JAK2 V617F mutation in Taiwanese was
comparable with that of other ethnic groups, although our result
was among the highest ones (Table 2)14,16e18,21,24e36. The difference
in the prevalence of JAK2 V617F mutation may result from the
difference in sample size, the use of different source of samples for
testing, and the different methods used for detecting mutation.
Since JAK2 V617F mutation has an important diagnostic implicationin MPNs including ET, we recommend the use of a more sensitive
method such as AS PCR for its detection.
The presence of JAK2 V617F mutation has been found to be
associated with several clinical and hematologic abnormalities in
ET patients in this study. In a univariate analysis, old age (65 years
old), higher hemoglobin, and higher leukocyte count were signiﬁ-
cantly associated with JAK2 V617F mutation. The degree of the
association between lower platelet counts and JAK2 V617F muta-
tion in the present study was only at borderline. Similar ﬁndings
were also reported in several studies (Table 2). Regarding the
association of old age, Randi et al28 have found that the percentage
of mutated patients and the JAK2 V617F allele burden increased
progressively with age. These phenotypic effects of JAK2 V617F
mutation are very distinctive features in patients with ET. Based on
the mutational status of JAK2 V617F, ET patients can be separated
into two distinct subtypes. The JAK2 V617F mutated patients who
are generally older have higher hemoglobin level and WBC count,
and lower platelet count. In a multivariate analysis using binary
logistic regression model, only higher hemoglobin level remained
signiﬁcantly associated with JAK2 V617F mutation. The presence of
JAK2 V617F mutation may skew the presenting phenotype and the
bonemarrow histology of ET toward amore “erythremic” feature32.
This was consistent with the ﬁnding that the prevalence of JAK2
V617F mutation was highest (more than 90%) in patients with
polycythemia vera. It is likely that the acquisition of JAK2 V617F
mutation may have a distinct biological effect on ET patients,
although this is a late genetic event in some ET patients37.
The association between JAK2 V617Fmutation and thrombosis is
a controversial issue; in our study, such an association was not
found. However, in a recent reviewed including 21 studies
involving patients with ET, Lussana et al38 found that the risk of
both venous and arterial thrombosis was signiﬁcantly increased in
able 2
tudies evaluating phenotypic relevance of JAK2 V617F allele according to its presence/absence in patients with ETa,26.
Reference no. This
study
27 24 25 21 28 14 29 16 18 17 30 31 33 34 35 36
Authors Lin et al Cho
et al
Wong
et al
Hsiao
et al
Wong
et al
Randi
et al
Campbell
et al
Antonioli
et al
Wolanskyj
et al
Cheung
et al
Kittur
et al
Pemmaraju
et al
Finazzi
et al
zki
l
Heller
et al
Alvarez-
Larran et al
Vannucchi
et al
Antonioli
et al
Year 2012 2009 2011 2007 2008 2011 2005 2005 2005 2006 2007 2007 2007 7 2006 2007 2007 2008
Patient no. 82 108 102 53 95 132 776 130 150 60 176 80 179 50 126 639 260
V617F-positive
patient no.
(% of total)
55 (67) 61 (56.5) 35 (34) 35 (66) 60 (63) 87 (65.9) 414 (53) 74 (57) 73 (49) 29 (48) 96 (55) 38 (47) 103 (57) (57) 24 (48) 44 (43) 382 (60) 165 (63)
Hematologic
characteristics
Higher Hb
and/or Htc
Yes No No Yes No d Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes
Higher WBC Yes Yes Yes Yes No d Yes No Yes No Yes No Yes No No Yes Yes
Lower Plt count No No No No Yes d Yes Yes No No Yes No Yes Yes Yes Yes Yes
Clinical characteristics
Older age Yes No Yes No Yes Yes Yes No Yes No Yes Yes d Yes d Yes Yes
Gender No No Yes No No No No No No No No d No No No No No
Disease duration No Yes No d No d No No No No d Yes No No d No No
Pruritus d d d d d d d d d d d d d d d No No
Systemic symptoms No d No d d d d d No d d d d d d No No
Palpable
splenomegaly
d d d d d d Yes d No d No d d d d Yes No
Major CV events No No d Yes Yes No No No No Yes No No Yes Yes No No No
Microvessel disease d d d d d d d d No d No No d No d d Yes
Major hemorrhages No No d No No d No No No d d d d d No No No
CHT treatment d No No d No d d d No d d d No No d No No
Evolution to MF d No d d d d No d No d d No d No No d
Evolution to AML d No d d d d No d No d d No d d No d
Evolution to PV d d d d d d Yes d Yes d No d d d Yes No d
Overall survival d No d d d d No d Yes d No d d d d d d
eprinted and adapted with permission from Macmillan Publishers Ltd: Leukemia (31), copyright (2008).
igher Hb/Htc, WBC or platelet count refers to the comparison of patients harboring the JAK2 V617F mutation versus wild-type patients. The line indicates that no inf ation is available.
ML¼ acute myelogenous leukemia; CHT treatment¼ percentage of patients who received chemotherapy; CV¼ cardiovascular events; ET¼ essential thrombocythe a; Hb¼ hemoglobin; Htc¼ hematocrit; MF¼ post-ET
yeloﬁbrosis; Plt¼ platelet count; WBC¼white blood cell count.
a Only studies reporting at least 50 total patients were included.
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H.-C. Lin et al.44JAK2 V617F mutated patients. Nevertheless, the presence of JAK2
V617F mutation has not yet been listed as a risk factor for throm-
bosis in ET39. Currently, ET patients are considered at high risk if
they are older than 60 years of age or if there is a history of previous
thrombosis.
There were several limitations in the present study, including
the use of different sources of blood samples for the detection of
JAK2V617Fmutation (some of the samples were collectedwhile the
patients were being treated with cytoreductive therapy such as
hydroxyurea) and a relatively short follow-up period in this cohort.
Nevertheless, we have found a high prevalence of JAK2 V617F
mutation and its association with characteristic phenotypes
including old age, higher hemoglobin level, and higher leukocyte
count in Taiwanese adult patients with ET.
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